Key Insights

Highlights

Success Rate

83% trial completion

Published Results

25 trials with published results (15%)

Research Maturity

86 completed trials (51% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

10.1%

17 terminated out of 168 trials

Success Rate

83.5%

-3.0% vs benchmark

Late-Stage Pipeline

5%

9 trials in Phase 3/4

Results Transparency

29%

25 of 86 completed with results

Key Signals

25 with results83% success17 terminated

Data Visualizations

Phase Distribution

137Total
Not Applicable (63)
Early P 1 (1)
P 1 (22)
P 2 (42)
P 3 (5)
P 4 (4)

Trial Status

Completed86
Recruiting21
Unknown20
Terminated17
Active Not Recruiting15
Withdrawn6

Trial Success Rate

83.5%

Benchmark: 86.5%

Based on 86 completed trials

Clinical Trials (168)

Showing 20 of 20 trials
NCT03141437Not ApplicableActive Not RecruitingPrimary

Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer

NCT07273812Not ApplicableNot Yet Recruiting

Evaluating an AI-Based Mobile Application for Chemotherapy Support in Breast Cancer Patients

NCT03935282Not ApplicableCompletedPrimary

Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors

NCT06072612Phase 3Recruiting

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

NCT03328026Phase 1Completed

Combination Study of SV-BR-1-GM With Retifanlimab

NCT06268665Phase 2Recruiting

Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy

NCT05505643Not ApplicableRecruiting

Cryoablation vs Lumpectomy in T1 Breast Cancers

NCT06100068Not ApplicableCompletedPrimary

HOBBIT 3: Mental Exercises and Temporal Alteration

NCT04799535Recruiting

Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring

NCT05169567Phase 3Active Not RecruitingPrimary

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

NCT02992782Not ApplicableCompletedPrimary

Decongestive Exercise and Compression for Breast Cancer Related Lymphedema Management

NCT02284919Phase 1Active Not Recruiting

[18F]ISO-1 Positron Emission Tomography (PET/CT) in Primary Breast Cancer

NCT06672302RecruitingPrimary

A Prospective Study to Develop and Clinically Validate an in Vitro Diagnostic Medical Device That Uses Blood to Classify Patients at High Risk for Breast Cancer

NCT06056414Not ApplicableCompletedPrimary

Study of Anxiety After a Session of Energy Resonance by Cutaneous Stimulation

NCT05949983Not ApplicableRecruitingPrimary

Health Economic Evaluation of an Adapted Physical Activity Program for Women With Breast Cancer

NCT02950259Phase 1CompletedPrimary

Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)

NCT03445637CompletedPrimary

Post Marketing Surveillance Study to Observe Safety and Efficacy of IBRANCE®

NCT05889988Active Not RecruitingPrimary

A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients

NCT04583124Not ApplicableCompletedPrimary

Adjusting the Dose of Therapeutic Exercise to Prevent Neurotoxicity Due to Anticancer Treatment (ATENTO)

NCT04652609Not ApplicableRecruitingPrimary

Preventing Chemotherapy-induced Peripheral Neuropathy Using PRESIONA Exercise Program

Scroll to load more

Research Network

Activity Timeline